{"id":3846,"date":"2025-05-13T17:38:41","date_gmt":"2025-05-13T14:38:41","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=3846"},"modified":"2025-05-13T17:47:11","modified_gmt":"2025-05-13T14:47:11","slug":"elevidys-gene-therapy-approved-in-japan","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/es\/elevidys-gene-therapy-approved-in-japan\/","title":{"rendered":"Sarepta Therapeutics anuncia la aprobaci\u00f3n en Jap\u00f3n de ELEVIDYS, una terapia g\u00e9nica para tratar la distrofia muscular de Duchenne"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Las personas de 3 a menos de 8 a\u00f1os que no presenten deleciones en los exones 8 y\/o 9 del gen DMD y que presenten un resultado negativo en la prueba de anticuerpos anti-AAVrh74 pueden usar ELEVIDYS. Esta es la primera aprobaci\u00f3n mundial que cubre a menores de cuatro a\u00f1os.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>M\u00e1s informaci\u00f3n:<\/strong> <a href=\"https:\/\/dmdwarrior.com\/es\/frequently-asked-questions-about-elevidys-used-for-duchenne-muscular-dystrophy\/\" target=\"_blank\" rel=\"noreferrer noopener\">Preguntas frecuentes sobre el uso de Elevidys para la distrofia muscular de Duchenne<\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">La terapia g\u00e9nica ELEVIDYS aprobada en Jap\u00f3n<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Sarepta Therapeutics, l\u00edder en medicina gen\u00e9tica de precisi\u00f3n para enfermedades raras, anunci\u00f3 hoy que el Ministerio de Salud, Trabajo y Bienestar de Jap\u00f3n (MHLW) aprob\u00f3 ELEVIDYS (delandistr\u00f3geno moxeparvovec) para el tratamiento de la distrofia muscular de Duchenne (DMD) bajo la v\u00eda de aprobaci\u00f3n condicional y limitada en el tiempo en Jap\u00f3n.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Leer m\u00e1s:<\/strong> <a href=\"https:\/\/dmdwarrior.com\/es\/will-elevidys-receive-approval-from-the-european-medicines-agency-ema\/\">\u00bfRecibir\u00e1 Elevidys la aprobaci\u00f3n de la Agencia Europea de Medicamentos (EMA)?<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>People aged 3 to under 8 who do not have deletions in exons 8 and\/or 9 of the DMD gene and who test negative for anti-AAVrh74 antibodies are eligible to use ELEVIDYS. This is the first worldwide approval that covers people under the age of four. Learn More: Frequently Asked Questions About Elevidys Used for [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3847,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[33,61,142],"class_list":["post-3846","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-elevidys","tag-gene-therapy","tag-japan"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/3846","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/comments?post=3846"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/3846\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media\/3847"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media?parent=3846"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/categories?post=3846"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/tags?post=3846"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}